Further studies have supported a role for PPARγ in reversing vascular remodeling in preclinical PAH models [106] and suggest that this mediation occurs via inhibition of TGF-β1 signaling [107]. This evidence concerns the gene TGFB1 and pulmonary arterial hypertension.